Crinetics (CRNX) COO Jeff Knight granted 55,000 options and 34,000 RSUs

Rhea-AI Filing Summary

Crinetics Pharmaceuticals, Inc. Chief Operating Officer Jeff E. Knight reported receiving new equity awards. He was granted stock options for 55,000 shares of common stock at an exercise price of $0.0000 per share and 34,000 restricted stock units representing common shares.

The RSUs vest with 25% of the award vesting annually beginning on March 1, 2027, providing staggered delivery of common shares over four years. The stock options vest in forty-eight equal monthly installments starting on February 23, 2026, creating a four-year monthly vesting schedule tied to continued service.

After these awards, Knight directly owned 121,929 shares of common stock, which includes 438 shares acquired under the company’s employee stock purchase plan, as well as 55,000 stock options from this grant.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Knight Jeff E.

(Last) (First) (Middle)

C/O CRINETICS PHARMACEUTICALS, INC.

6055 LUSK BOULEVARD

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/23/2026		A		34,000	A	$0(1)	121,929(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$43.79	02/23/2026		A		55,000		(3)	02/23/2036	Common Stock	55,000	$0	55,000	D

Explanation of Responses:

1. The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2027.

2. Includes 438 shares acquired under the Issuer's Employee Stock Purchase Plan.

3. The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026.

Remarks:

	/s/ Tobin Schilke, as attorney-in-fact	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did CRNX COO Jeff E. Knight receive in this Form 4?

Jeff E. Knight received 55,000 stock options and 34,000 restricted stock units in Crinetics Pharmaceuticals. The options give a right to buy common shares, while the RSUs represent shares deliverable over time, subject to the vesting schedules described in the filing.

How do Jeff E. Knight’s new restricted stock units in CRNX vest?

The restricted stock units vest in four annual installments, with 25% vesting each year starting March 1, 2027. This structure spreads delivery of Crinetics Pharmaceuticals common shares over several years, aligning the award with longer-term service and performance horizons.

What is the vesting schedule for Jeff E. Knight’s 55,000 CRNX stock options?

The 55,000 stock options vest in forty-eight equal monthly installments beginning February 23, 2026. This creates a four-year vesting period, giving Jeff E. Knight gradual exercisability of options tied to continued employment with Crinetics Pharmaceuticals over that timeframe.

What was Jeff E. Knight’s CRNX common stock ownership after these awards?

After the reported grants, Jeff E. Knight beneficially owned 121,929 shares of Crinetics Pharmaceuticals common stock directly. This total includes 438 shares acquired under the company’s Employee Stock Purchase Plan, along with previously held shares reported in earlier filings.

Does this CRNX Form 4 show Jeff E. Knight buying or selling shares on the market?

The Form 4 shows equity awards granted to Jeff E. Knight, not open-market buying or selling. Both transactions are coded as acquisitions related to grants of stock options and restricted stock units, with no reported sale transactions in this particular filing.

What does the Employee Stock Purchase Plan note mean in the CRNX Form 4?

The filing notes that Knight’s total common stock holdings include 438 shares acquired under Crinetics Pharmaceuticals’ Employee Stock Purchase Plan. This indicates part of his ownership comes from a company program allowing employees to purchase shares, usually through payroll deductions.